ライフサイエンスコーパス: ER-beta

1 nd binding domain of estrogen receptor beta (ER-beta).

2 ctivation of estrogen receptor subtype beta (ER-beta).

3 at ADA3 directly interacts with ER alpha and ER beta.

4 nscriptional activities of both ER alpha and ER beta.

5 s containing the consensus ERE sequence than ER beta.

6 activity on ER alpha while being inactive on ER beta.

7 for one of the two ER subtypes, ER alpha or ER beta.

8 njury is totally preserved in the absence of ER beta.

9 cates the involvement of another ER, perhaps ER beta.

10 vity by hPMC2 is enhanced in the presence of ER beta.

11 R alpha, either alone or in combination with ER beta.

12 will require antagonism of ER alpha but not ER beta.

13 ressed more abundantly on EPCs compared with ER beta.

14 on through the two ER subtypes, ER alpha and ER beta.

15 ge (T-H) are mediated via estrogen receptor (ER)beta.

16 xpress both estrogen receptor (ER)-alpha and ER-beta.

17 ranslated exon 0N and the promoter region of ER-beta.

18 CGIs, led to transcriptional inactivation of ER-beta.

19 oximately 7.5% of oxytocin (OT) MNCs express ER-beta.

20 ptor (ER) alpha and the more recently cloned ER-beta.

21 and anticancer effects that are mediated by ER-beta.

22 contained cells that were immunostained for ER-beta.

23 es and subjected to binding experiments with ER-beta.

24 GGTCAnnnTGACC, which bind both ER-alpha and ER-beta.

25 780 blocks activation by ER-alpha but not by ER-beta.

26 oprotection occurs through the activation of ER-beta.

27 ibit robust expression of estrogen receptor (ER)-beta.

28 , whereas CAV3 is necessary for ER alpha and ER beta activation of mGluR2/3.

29 udy, we evaluated the effect of ER-alpha vs. ER-beta activation on ECM production, deposition, and un

30 We hypothesize that estrogen protects by ER-beta activation, which leads to S-nitrosylation (SNO)

31 post-ischemic hippocampal injury by means of ER-beta activation.

32 s of the highly selective estrogen receptor (ER) beta agonist indazole chloride (Ind-Cl) on functiona

33 etabolite and a selective estrogen receptor (ER) beta agonist, is approximately 400x more potent than

34 agonist [propylpyrazoletriol (PPT)], and an ER-beta agonist [WAY-200070 (WAY)] with TNF-alpha or pla

35 The ER-beta agonist DPN did not mimic the effect of estradio

36 Additionally, periodic ER-beta agonist treatments every 48 hr improved post-isc

37 alpha agonist), or diarylpropionitrile (DPN, ER-beta agonist) before allergen challenge to determine

38 or an estrogen receptor (ER)-alpha (but not ER-beta) agonist into the dorsal hippocampus rapidly imp

39 ER alpha and ER beta agonists PPT and DPN inhibited and 4-OHT increas

40 which were developed as nuclear ER-alpha and ER-beta agonists/antagonists, have previously been impli

41 eric ER(alpha/beta) (AF-1alpha/AF-2beta) and ER(beta/alpha) (AF-1beta/AF-2alpha) proteins that resemb

42 scriptional activation studies with chimeric ER(beta/alpha) and ER(alpha/beta) showed that only ER(al

43 ivate transcription from an Sp1 element, not ER(beta/alpha).

44 ern immunoblotting confirmed the presence of ER beta and AR in platelets.

45 n erythroleukemia (HEL) cells also contained ER beta and AR transcripts.

46 l human CD34(+) stem cells contained RNA for ER beta and AR, which increased with cell differentiatio

47 The AD-like effect of estradiol involved ER beta and G-protein coupled receptor 30, whereas its b

48 pression of mRNA for both estrogen receptor (ER) beta and transforming growth factor beta1 was determ

49 Furthermore, ER-beta and BDNF do not colocalize in any brain region.

50 tence of additional relationships related to ER-beta and enzymes involved in hormone metabolism.

51 used to determine the mechanism of action of ER-beta and its ligands.

52 re protects hearts largely via activation of ER-beta and nitric oxide/SNO signaling.

53 s of PR and pS2, DU145 expressed messages of ER-beta and PR, and PC-3 cells exhibited ER-alpha, ER-be

54 tions requiring the ligand binding domain of ER-beta and through abrogation of the ability of PGC-1 t

55 The discovery of estrogen receptor beta (ER beta) and subsequent localization of its mRNA in the

56 ncreases in estrogen receptors (ER-alpha and ER-beta) and a decrease in progesterone receptor levels,

57 etermine the role of estrogen receptor beta (ER-beta) and its ligands on adipose biology.

58 Estrogen receptor beta (ER-beta) and its selective ligand reprogrammed preadipoc

59 lar receptors, alpha (ER alpha) and/or beta (ER beta), and the progestin receptor (PR).

60 alpha (ER-alpha) and estrogen receptor beta (ER-beta), and antagonize the activity of beta-estradiol

61 fter the raloxifene treatment, PC3 (ER-alpha/ER-beta+) and DU145 (ER-beta+ only) cells were selected

62 ive brain area reported to express ER alpha, ER beta, and PR.

63 ng the biological roles of both ER alpha and ER beta, and they might form the basis for the developme

64 osphorylation of the corresponding region of ER beta, and this correlates with the lack of forskolin/

65 replacement and the number of cortical GABA, ER-beta, and ER-beta/GABA double-labeled neurons was exa

66 a and PR, and PC-3 cells exhibited ER-alpha, ER-beta, and pS2 mRNA.

67 X is functionally distinct from ER-alpha and ER-beta, and that, like ER-alpha, it is re-expressed in

68 contrast, in DU145 cells, which express only ER-beta, antiestrogens, but not estrogens, are growth in

69 versed by cotreatment of DU145 cells with an ER-beta antisense oligonucleotide, hence lending additio

70 expression plasmid pCI-ER alpha, but not pCI-ER beta, aromatase activity was elevated by 17beta-estra

71 avourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be de

72 constitutive activity of estrogen receptor (ER) beta as an important regulator of metabolic diseases

73 e results lend further support to a role for ER-beta as a poor prognostic factor in breast cancer.

74 Silencing of hippocampal ER-beta attenuated E2-mediated ischemic protection sugge

75 odies were made against a peptide within the ER-beta B domain.

76 for studying ER-beta signaling and design of ER-beta-based therapies.

77 try to further characterize the phenotype of ER-beta-bearing cells by double labeling for the GABAerg

78 The findings indicated that ER-beta-bearing inhibitory neurons project onto other GA

79 Thus, ER-beta behaves like a noncanonical type-I receptor, and

80 inhibitory activities and high ER-alpha and ER-beta binding affinities of several of the resulting a

81 with estrogen receptor alpha (ER alpha) and ER beta bound to a variety of ligands.

82 P-dependent activation of gene expression by ER beta but not ER alpha, indicating that the former sub

83 ligand-binding domain of estrogen receptor (ER) beta but also a second site on its surface.

84 he developing brain, is neither ER-alpha nor ER-beta but a novel, plasma membrane-associated, putativ

85 enous gene, this element is nonresponsive to ER-beta but confers estrogen-dependent inhibition of tra

86 s been demonstrated that LNCaP cells express ER-beta but not ER-alpha and that tamoxifene induces apo

87 P was shown to recognize in vitro translated ER beta, but not ER alpha, as well as a 60-kDa protein f

88 Interestingly, only transcripts of ER-beta, but not those of ER-alpha, were found in our pr

89 The activation of ER-beta by DPN treatment leads to increased protein SNO

90 s hormone, no studies have addressed whether ER beta can be similarly regulated.

91 ER-beta can play an important role in CRC development an

92 The inhibition of anoikis by ER-beta-catenin can be abolished by a mitogen-activated

93 Evidence is also provided to show that ER-beta-catenin down-regulates cadherin protein levels.

94 The activation of ER-beta-catenin signaling rescues RK3E cells from anoiki

95 se relationship exists between the extent of ER-beta CGI methylation and receptor expression in norma

96 the PVN (12.57% +/- 1.99%), but there was no ER-beta colocalization with TRH.

97 Both ER alpha and ER beta contribute to E2-mediated EPC activation and tis

98 d the major groove of the DNA helix, but the ER beta DBD and hinge region failed to bend ERE-containi

99 R and Western blot analysis for ER-alpha and ER-beta demonstrated that all three cell lines express E

100 gene for a likely gene duplication product, ER-beta, did not have these effects.

101 (i) ER-beta1 is the obligatory partner of an ER-beta dimer, whereas the other isoforms function as va

102 Activation of ER-beta diminishes ECM deposition via suppressing the NF

103 the loss of expression of estrogen receptor (ER)-beta during the development of prostate cancer (PCa)

104 discernable activity with ER-alpha, but with ER-beta, E(2) was displaced with an IC(50) of 125 microM

105 Recently, ER-beta (ERbeta) mRNA and protein were shown to be expre

106 estrogen receptor-alpha (ER-alpha, Esr1) or ER-beta (Esr2) increased ILC2-mediated airway inflammati

107 Comparisons were made between ER-beta, estrogen receptor-alpha (ER-alpha), and androge

108 lly prepared aglycons bound significantly to ER-beta, except for 27-deoxyactein aglycon, which showed

109 Estrogen receptor-alpha (ER-alpha) and ER-beta exhibit fine differences in their distributions

110 Thus, ER-beta exhibits extensive colocalization with a subclas

111 ling and discovered that axons from cortical ER-beta-expressing inhibitory neurons terminate on BDNF-

112 ssociated with reduced risk of ER-alpha- and ER-beta-expressing NSCLC.

113 arcinogenesis was characterized by a loss of ER-beta expression at the protein and transcript levels

114 Thus, osmotic modulation of ER-beta expression in MNCs may augment or attenuate an i

115 for neuronal activation in the regulation of ER-beta expression in MNCs.

116 ndometrium (4.9) mainly as a result of lower ER-beta expression in the former.

117 after osmotic manipulation, suggesting that ER-beta expression was not driven by ligand availability

118 The osmotically induced decrease in ER-beta expression was selective for MNCs because ER-bet

119 promoter CGI, which correlated with loss of ER-beta expression, was detected in microdissected sampl

120 ted with cytoplasmic ER-alpha and/or nuclear ER-beta expression-defined NSCLC in postmenopausal women

121 profiling; however, the estrogen metabolism/ER-beta factor seemed to be distinctive.

122 lin D1, and aromatase], "estrogen metabolism/ER-beta factor" (ER-beta, peroxisome proliferator-activa

123 , and in contrast to the estrogen metabolism/ER-beta factor, higher current body mass index among pre

124 d the major groove of the DNA helix but that ER beta failed to induce a directed DNA bend.

125 nd the number of cortical GABA, ER-beta, and ER-beta/GABA double-labeled neurons was examined.

126 ber of perirhinal neurons double-labeled for ER-beta/GABA was reduced by 28% (P<0.01 compared to vehi

127 sections were double- or triple-labeled for ER-beta, GABAergic, and BDNF immunomarkers.

128 s were intact in male mice lacking the novel ER-beta gene.

129 henotype in mice that lack both ER-alpha and ER-beta genes (alphabetaERKO).

130 gues can activate ER alpha(Glu353-->Ala) and ER beta(Glu305-->Ala) with very large selectivites, demo

131 ory of both ERs and discuss the implications ER beta has to patients with breast cancer.

132 cently characterized estrogen receptor-beta (ER-beta) has not been examined in vivo.

133 cloning of a second estrogen receptor (ER), ER beta, has prompted a reevaluation of the role of ERs

134 .8% (intact) and 94.5% +/- 1.4% (ovx) of all ER-beta-immunoreactive cells coexpress parvalbumin, and

135 - 3.1% (intact) and 26.0% +/- 5.2 % (ovx) of ER-beta-immunoreactive cells coexpress PV.

136 We find that a large proportion of ER-beta-immunoreactive cells within the cortex, amygdala

137 Almost all ER-beta-immunoreactive cells within the subiculum, a maj

138 l animals, but they were virtually devoid of ER-beta-immunoreactivity (IR) in hyper-osmotic animals.

139 In normal prostate, ER-beta immunostaining was predominately localized in th

140 more potent activator of transcription than ER beta in bone, uterine, and mammary cells.

141 and GCSh point towards an important role for ER beta in cellular protection against oxidative stress.

142 elped to delineate the roles of ER alpha and ER beta in modulating transcription of genes containing

143 induced higher levels of transcription than ER beta in the presence of 17 beta-estradiol.

144 try (ICC) to investigate the distribution of ER beta in the rat CNS.

145 g through the AP1 element, overexpression of ER beta in tumors expressing both ER subtypes may explai

146 onstrated the presence of estrogen receptor (ER) beta in cells of the megakaryocytic lineage.

147 The localization of estrogen receptor (ER)beta in mitochondria suggests ERbeta-dependent regula

148 These data highlight a new role for ER-beta in adipose biology and its potential to be a saf

149 Numerous MNCs were positive for ER-beta in control animals, but they were virtually devo

150 ditional support to a central role played by ER-beta in mediating growth-inhibitory action of antiest

151 Expression of ER-beta in metastases may have been influenced by the lo

152 state cancer cells in vitro, the presence of ER-beta in metastatic cells may have important implicati

153 elease, this suggests an inhibitory role for ER-beta in MNCs.

154 to investigate the presence of ER-alpha and ER-beta in normal and malignant colon tissue.

155 estrogen action was signaled exclusively via ER-beta in normal human PrECs.

156 both estrogen receptor-alpha (ER-alpha) and ER-beta in ovarian, breast and endometrial cancer cell l

157 The importance of ER-beta in tamoxifen resistance was validated using tamo

158 entage of oxytocin (OXY) neurons coexpressed ER-beta in the PVN (84.39% +/- 2.99%), there was very li

159 strogen receptors alpha (ER alpha) and beta (ER beta) in EPC biology are largely unknown.

160 estrogen receptor (ER) subtype, ER alpha and ER beta, in the injured brain.

161 estrogen receptor-alpha (ER alpha), but not ER beta, inhibited estrogen-stimulated telomerase functi

162 t binds to both receptors, but enhances only ER beta interaction with SRC1 and SRC3 while exhibiting

163 pin-releasing hormone neurons also expressed ER-beta ir in the PVN (12.57% +/- 1.99%), but there was

164 utions of ER-alpha immunoreactivity (ir) and ER-beta ir were nonoverlapping in the PVN and SON.

165 ta expression was selective for MNCs because ER-beta-IR remained unaltered in PVN parvocellular neuro

166 FOS-IR in parvocellular neurons that retain ER-beta-IR suggest a role for neuronal activation in the

167 Expression of FOS-IR in MNCs with attenuated ER-beta-IR, and the absence of FOS-IR in parvocellular n

168 A critical step in understanding the role of ER beta is demonstrating that the mRNA is translated int

169 Estrogen receptor (ER) beta is more potent than ERalpha at repressing the -

170 Estrogen receptor (ER)-beta is thought to exert anti-proliferative effects

171 these studies indicate that ligand-activated ER-beta is a potential therapeutic target to combat obes

172 first evidence that epigenetic regulation of ER-beta is a reversible and tumor stage-specific process

173 Given the recent finding that cortical ER-beta is almost exclusively localized to parvalbumin-i

174 Our data indicate that ER-beta is expressed at higher levels in Caco-2 cells an

175 Because ER-beta is thought to function as an inhibitor of prosta

176 abundant cortical nuclear estrogen receptor, ER-beta, is present in GABAergic neurons, prompting us t

177 The ER-beta isoform is functionally similar to ER-alpha but

178 Shorter ER-beta isoforms were detected in the ER-alpha-negative

179 GnRH-1 neurons expresses estrogen receptor (ER) beta, it is unclear whether E2 acts directly on GnRH

180 n functions signaled through hER-alpha66 and ER-beta; it also transduces membrane-initiated estrogen-

181 we used ER alpha-knockout (ER alpha KO) and ER beta-knockout (ER beta KO) mice in an animal model of

182 To test the specificity of DPN, we treated ER-beta-knockout mice with DPN.

183 cardioprotective effect of DPN was found in ER-beta-knockout mice, indicating that the DPN-induced c

184 fects of ER-beta ligand were not observed in ER-beta-knockout mice.

185 knockout (ER alpha KO) and ER beta-knockout (ER beta KO) mice in an animal model of stroke.

186 We ovariectomized ER alpha KO, ER beta KO, and the respective wild-type mice and implan

187 adiol differ dramatically among ER alpha KO, ER beta KO, and wild-type mice.

188 In addition to higher estrogen receptor (ER) beta levels, enhanced ERbeta activity was detected i

189 discriminate between different ER alpha and ER beta ligand complexes suggests that the biological ef

190 An estrogen receptor (ER) beta ligand (LY3201) with a preference for ERbeta ov

191 The highly selective estrogen receptor (ER) beta ligand chloroindazole (IndCl) shows particular

192 litis (EAE) mice with the estrogen receptor (ER) beta ligand diarylpropionitrile (DPN) has been shown

193 The antiobesity effects of ER-beta ligand were not observed in ER-beta-knockout mic

194 s studies have shown that estrogen receptor (ER) beta ligands could inhibit experimental autoimmune e

195 Thus, ER beta may be a useful prognostic factor in patients wi

196 Regardless of these differences, ER beta-mediated regulation of GST-Pi and GCSh point tow

197 xpression of ADA3 enhances the ER alpha- and ER beta-mediated sequence-specific transactivation.

198 Based on our recent finding of anti-estrogen/ER-beta-mediated growth inhibition of prostate cancer ce

199 or propyl pyrazole triol in wild-type and in ER-beta-/- mice.

200 C/ in situ hybridization study revealed that ER beta mRNA and immunoreactivity were colocalized in ne

201 of these studies have demonstrated that (1) ER beta mRNA is translated into immunoreactive protein t

202 studies that a variety of estrogen receptor (ER) beta mRNA transcripts are expressed in human breast

203 prostate cancer cell lines, LNCaP expressed ER-beta mRNA along with transcripts of PR and pS2, DU145

204 Thus, the expression of ER-beta mRNA correlated inversely with changes in plasma

205 ol and testosterone were not correlated with ER-beta mRNA expression after osmotic manipulation, sugg

206 ia d-d-arginine VP and liquid diet increased ER-beta mRNA expression in MNCs (p < 0.05).

207 We examined the osmotic regulation of ER-beta mRNA expression in MNCs using quantitative in si

208 transcription-PCR revealed no difference in ER-beta mRNA levels between normal and malignant colon t

209 ell lines, in which it was demonstrated that ER-beta mRNA was significantly up-regulated in the resis

210 ER-beta mRNA was significantly up-regulated in the tamox

211 ochemistry demonstrated that the decrease in ER-beta mRNA was translated into depletion of receptor p

212 lines (LNCaP and DU145), that express little ER-beta mRNA, with a demethylating agent increased level

213 es were associated with nuclear ER-alpha- or ER-beta-negative NSCLC.

214 , in weanling rats sex affected ER alpha and ER beta neuronal densities in brainstem regions associat

215 d characterized a genuine estrogen receptor (ER) beta-null mouse line (named ERbeta(ST)(L-/L-)) and s

216 sion of the estrogen receptors (ER alpha and ER beta) on the globoid cells, activated astrocytes and

217 ER-beta only modestly affected FR-alpha promoter activit

218 reatment, PC3 (ER-alpha/ER-beta+) and DU145 (ER-beta+ only) cells were selected to further characteri

219 ting the first 18 amino acids of the longest ER-beta open reading frame reported to date, and polyclo

220 Targeting of ER beta or G-protein coupled receptor 30 might reveal a

221 tide oxytocin (OT) or the estrogen receptor (ER)-beta or ER-alpha had been selectively "knocked out"

222 ition of the four genes coding for ER-alpha, ER-beta, OT, and the OT receptor.

223 with beta-LGNDs demonstrated selectivity for ER-beta over ER-alpha.

224 VN (84.39% +/- 2.99%), there was very little ER-beta/OXY colocalization in the SON.

225 tase], "estrogen metabolism/ER-beta factor" (ER-beta, peroxisome proliferator-activated receptor-gamm

226 mediated ischemic protection suggesting that ER-beta plays a key role in mediating the beneficial eff

227 at the activation of estrogen receptor-beta (ER-beta) plays an important cardioprotective role agains

228 vasopressin-immunoreactive neurons were also ER-beta positive in the PVN (66.14% +/- 2.47%) and SON (

229 sk of NSCLC characterized as ER-alpha and/or ER-beta positive.

230 In general, ER beta-positive neurons in the brainstem regions examin

231 antitate areas and densities of ER alpha and ER beta-positive neurons within medullary regions associ

232 In normal breast tissue, expression of ER beta predominated, with 22% of samples exclusively ex

233 or alpha (ER alpha), estrogen receptor beta (ER beta), progesterone receptor (PR), and androgen recep

234 ains (E domains) of human/mouse ER alpha and ER beta, progesterone receptors A and B, and the androge

235 Immunofluorescence microscopy showed that ER beta protein was present in glycoprotein (GP) IIb(+)

236 l increased the density of both ER-alpha and ER-beta protein clusters along dendrites.

237 ER-beta-specific antibodies to characterize ER-beta protein expression in breast cancer cell lines a

238 nant colon tissue showed a selective loss of ER-beta protein expression when compared to normal colon

239 on is associated with a marked diminution of ER-beta protein expression, possibly through a posttrans

240 By Western blot analysis, we show that ER-beta protein is expressed in all cancer cell lines te

241 pressed estrogen receptor (ER)alpha, but not ER-beta protein levels, and abrogated downstream estroge

242 tients with 5-FU-resistant tumors expressing ER-beta protein.

243 howed variation in the size of the expressed ER-beta protein.

244 Both ER(alpha) and ER(beta) proteins physically interact with Sp1 (coimmuno

245 ER-beta/PV double-labeled cells are also observed within

246 ER-beta/PV double-labeled cells represent 23.3% +/- 1.6%

247 Estrogen receptor beta (ER-beta) regulates diverse physiological functions in th

248 ve protein throughout the rat brain, and (2) ER beta resides in the cell nucleus.

249 reated ovariectomized C57BL/6J mice with the ER-beta selective agonist 2,2-bis(4-hydroxyphenyl)-propr

250 ligand 16alpha-iodo-17beta-estradiol and the ER-beta selective ligand genistein failed to elicit ERK

251 An ER-beta-selective ligand increased markers of tricarboxy

252 This phenotype was partially reversed by ER-beta-selective ligand.

253 We evaluated the pharmacological effect of ER-beta-selective ligands (beta-LGNDs) in animal models

254 ther with the inability of the ER-alpha- and ER-beta-selective ligands to elicit ERK phosphorylation,

255 However, the potential of ER-beta-selective ligands to offset obesity is not clear

256 sistent with the 530-amino acid, full-length ER-beta sequence.

257 2-mediated responses were due to ER alpha or ER beta signaling, ER alpha-knockout (alphaERKO) or ERbe

258 viously unrecognized directions for studying ER-beta signaling and design of ER-beta-based therapies.

259 ivo findings that methylation is involved in ER-beta silencing.

260 and cell context-dependent ER(alpha)/Sp1 and ER(beta)/Sp1 action using an E2-responsive construct (pS

261 E2 did not affect or significantly decrease ER(beta)/Sp1 action, and antiestrogens had minimal effec

262 The present study used a new ER beta-specific polyclonal antiserum (Z8P) and immunocy

263 fects were mimicked by an estrogen receptor (ER) beta-specific agonist and were blocked by the classi

264 17-diol (ICI 182,780)] and the ER-alpha- and ER-beta-specific agonists [1,3,5-tris(4-hydroxyphenyl)-4

265 abolish receptor binding, and ER-alpha- and ER-beta-specific antibodies interact with complexes form

266 he RNA expression studies, we have developed ER-beta-specific antibodies to characterize ER-beta prot

267 ice had decreased expression of ER-alpha and ER-beta subtypes and ER transcriptional activity was als

268 pression of estrogen receptor (ER)-alpha and ER-beta subtypes in GS-prone and GS-resistant glomeruli

269 factor requirements, domains of ER alpha and ER beta sufficient for forskolin/IBMX activation, and th

270 s proliferation via oestrogen receptor-beta (ER-beta), the catecholoestradiols mediate P-UAEC prolife

271 In cells containing either ER-alpha or ER-beta, the 3'-element behaves as a traditional enhance

272 Because the prostate contains high levels of ER-beta, the present study investigated the effect of ra

273 ecause the prostate contains a high level of ER-beta, the present study investigated the effect of ra

274 act on the OT system at two levels: through ER-beta, they regulate the production of OT in the hypot

275 , with 22% of samples exclusively expressing ER beta; this was not observed in any of the breast tumo

276 n, we compared the abilities of ER alpha and ER beta to activate transcription and induce distortion

277 The different abilities of ER alpha and ER beta to induce change in DNA structure could foster o

278 a selective modulator of estrogen receptor (ER)beta to suppress inflammatory responses of microglia

279 nteracting with ER alpha, ERAP140 also binds ER beta, TR beta, PPAR gamma, and RAR alpha.

280 istinct mechanisms to stimulate ER alpha and ER beta transcriptional activity.

281 ivators stimulated cAMP-induced ER alpha and ER beta transcriptional activity.

282 and BPH-1 cells expressed both ER-alpha and ER-beta transcripts and no PR nor pS2 mRNA in PrEC and o

283 Expression levels of ER-alpha and ER-beta transcripts were related to those of two estroge

284 e after trauma-hemorrhage and female 129 Sve ER-beta-/- transgenic mice and ovariectomized wild-type

285 ER-beta variants were also detected.

286 urons with the highest percentage expressing ER-beta was found to be prolactin (PRL) immunoreactive i

287 its specificity for estrogen receptor-beta (ER-beta), was used to immunolocalize the receptor in his

288 lpha (ER-alpha), and estrogen receptor-beta (ER-beta), we found only sparse colocalization between ER

289 in the ligand-binding domain of ER-alpha and ER-beta, we were not surprised to find that SP500263 bin

290 In contrast sex differences in ER beta were found in fewer nuclei, but in those higher

291 , those tumors that coexpressed ER alpha and ER beta were node positive (P = 0.02; Fisher's exact tes

292 of estrogen receptor (ER)-alpha and those of ER-beta were expressed in our normal PrEC primary cultur

293 A and protein expression of ER-alpha but not ER-beta were suppressed by resveratrol in Ishikawa cells

294 dzein and genistein (compounds known to bind ER-beta) were performed to serve as positive controls.

295 terestingly hPMC2 interacts more strongly to ER beta when compared with ER alpha.

296 ural estrogen genistein at both ER-alpha and ER-beta, whereas AIB1 had no effect on either the potenc

297 monstrated that all three cell lines express ER-beta, whereas only PC3 and PC3M cells were positive f

298 d increased expression of estrogen receptor (ER)-beta, which upon activation down-regulated ASM proli

299 anslationally modified form of the long-form ER-beta, which has a predicted size of 59 kd based on po

300 d developmentally regulated, and neocortical ER-beta, which is intranuclear and expressed throughout